readthroughSign in
CompanyMOLNNasdaqSchlieren-Zurich, V8

Molecular Partners AG

Molecular Partners AG develops DARPin therapeutics for cancer, including radiopharmaceuticals for targeted alpha therapy and immune cell engagers.

10-QNov 16Latest SEC filing
Oct 29Latest story